HK inno.N licenses in mAbxience’s denosumab biosimilarMiguel Martínez-Cava2023-01-25T10:46:18+01:00January 25, 2023|News|
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals marketMiguel Martínez-Cava2022-08-01T17:18:20+02:00August 1, 2022|News|